SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that a $5 million milestone relating to progress on clinical product development strategy has been achieved under its over-the-counter (OTC) license agreement with Schering-Plough HealthCare Products, Inc. for proton pump inhibitor (PPI) products using Santarus’ patented PPI technology.
